DiogenX, a Marsille, France-based biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, raised €27.5M in Series A funding.
Backers included Roche Venture Fund, Eli Lilly and Company, Omnes, Boehringer Ingelheim Venture Fund, JDRF T1D Fund, and Adbio partners. As part of the financing, David Evans joined DiogenX’s board of directors.
The company intends to use the funds to advance the lead drug candidate towards clinical development in patients with type 1 diabetes (T1D).
Led by Benjamin Charles, CEO, DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Its lead program is focused on modulating the Wnt/β-catenin signalling pathway to regenerate pancreatic insulin-producing beta cells to offer a disease-modifying therapy for type 1 diabetes. It is currently in preclinical development.
The company, co-founded by Patrick Collombat, Jean-Pascal Tranié and Benjamin Charles, is based in Marseille, France, with research labs in Nice, France.
FinSMEs
10/05/2023